DAIC

JULY 10, 2024

Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal of the American College of Cardiology, JACC, shed light on the racial and ethnic disparities in diabetic cardiomyopathy (DbCM), which researchers note may have the potential to inform clinical practice, interventions, and policies.

Cardiomyopathy 113

Cardiomyopathy Diabetes Health Disparities Exercise 113

HeartRhythm

DECEMBER 28, 2024

Desmoplakin (DSP) variants are associated with left-predominant or biventricular arrhythmogenic cardiomyopathy. Exercise promotes penetrance and sustained ventricular arrhythmias (VA) in right-sided arrhythmogenic right ventricular cardiomyopathy, but its effect is unknown in DSP variant carriers.

Exercise 81

Exercise Cardiomyopathy Arrhythmia 81

JAMA Cardiology

SEPTEMBER 3, 2024

This substudy of the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) randomized clinical trial investigates if treatment with aficamten improves exercise response beyond peak oxygen uptake measured by cardiopulmonary exercise testing (..)

Exercise 56

Exercise Cardiomyopathy 56

Circulation

NOVEMBER 8, 2024

BACKGROUND:Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience reduced exercise capacity. Physical training improves exercise capacity in these patients, but whether the underlying effects of exercise are a result of central hemodynamic or peripheral improvement is unclear.

Exercise 49

Exercise Cardiomyopathy Quality of Life Pulmonary 49

American Heart News - Heart News

MAY 8, 2024

WASHINGTON and DALLAS (May 8, 2024) – The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM).

Cardiomyopathy 60

Cardiomyopathy Exercise 60

Heart BMJ

APRIL 25, 2024

Clinical introduction A patient in his 60s with a history of ischaemic cardiomyopathy and severely reduced left ventricular ejection fraction of 20% presents with worsening dyspnoea on exertion. mL/kg/min) despite maximal effort. The test was stopped due to shortness of breath. Plots 1 and 2 from the CPET are shown in figure 1A and B.

Exercise 52

Exercise Cardiomyopathy Defibrillator 52

NEJM Journal Watch - Cardiology

MAY 11, 2024

New recommendations include exercise prescription and treatment with cardiac myosin inhibitors.

Cardiomyopathy 80

Cardiomyopathy Exercise 80

HeartRhythm

MARCH 31, 2025

Arrhythmogenic cardiomyopathy (ACM) is an inherited disease, often of the desmosome, characterized by fibrofatty replacement of the myocardium and an increased risk of arrhythmia.

Exercise 40

Exercise Cardiomyopathy Arrhythmia 40

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Hypertrophic cardiomyopathy is the most common genetic cardiac disorder and is defined by the presence of left ventricular (LV) hypertrophy in the absence of a condition capable of producing such a magnitude of hypertrophy. Over the past decade, guidelines on the screening, diagnostic, and management protocols of pediatric primary (i.e.,

Pediatrics 87

Pediatrics Cardiomyopathy Exercise Heart Failure 87

Nature Reviews - Cardiology

MAY 27, 2024

Nature Reviews Cardiology, Published online: 28 May 2024; doi:10.1038/s41569-024-01044-8 Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiomyopathy 60

Cardiomyopathy Quality of Life Exercise 60

American College of Cardiology

APRIL 8, 2024

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic cardiomyopathy (DbCM), according to results from a Late-Breaking Clinical Trial.

Exercise 49

Exercise Cardiomyopathy Diabetes Article 49

HeartRhythm

MARCH 31, 2025

Pathogenic variants can lead to arrhythmogenic cardiomyopathy (PKP2-ACM). In PKP2-ACM patients, exercise negatively impacts arrhythmia incidence and severity, and catecholaminergic surges can precipitate life-threatening arrhythmias. Plakophilin-2 (PKP2) is a component of the desmosome.

Exercise 40

Exercise Cardiomyopathy Arrhythmia 40

HeartRhythm

MARCH 31, 2025

Pathogenic variants can lead to arrhythmogenic cardiomyopathy (PKP2-ACM). In PKP2-ACM patients, exercise negatively impacts arrhythmia incidence and severity, and catecholaminergic surges can precipitate life-threatening arrhythmias. Plakophilin-2 (PKP2) is a component of the desmosome.

Exercise 40

Exercise Cardiomyopathy Arrhythmia 40

HCPLive

MAY 9, 2024

Compass Pathways reports positive results for psilocybin in PTSD treatment, showing safety and symptom improvement in an open-label phase 2 study.

Exercise 72

Exercise Cardiomyopathy 72

American College of Cardiology

NOVEMBER 15, 2024

What is the effect of exercise training on left ventricular (LV) filling pressure measured during exercise in patients with hypertrophic cardiomyopathy (HCM) without left ventricular outflow tract (LVOT) obstruction?

Exercise 49

Exercise Cardiomyopathy Article 49

NEJM Journal Watch - Cardiology

APRIL 30, 2024

The highly selective aldose reductase inhibitor AT-001 did not improve exercise capacity in a randomized trial.

Cardiomyopathy 81

Cardiomyopathy Diabetes Exercise Outcomes 81

American College of Cardiology

NOVEMBER 20, 2024

In this week’s View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM).

Exercise 54

Exercise Cardiomyopathy Article 54

American College of Cardiology

JULY 2, 2024

What is the effect of AT-001, an aldose reductase inhibitor, on exercise capacity among individuals with diabetic cardiomyopathy (DbCM) with reduced exercise capacity and at high risk for progression to overt heart failure (HF)?

Cardiomyopathy 49

Cardiomyopathy Diabetes Exercise Heart Failure 49

Nature Reviews - Cardiology

APRIL 22, 2024

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01032-y According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.

Cardiomyopathy 56

Cardiomyopathy Exercise 56

HeartRhythm

APRIL 30, 2024

Introduction: Pathogenic desmoplakin (DSP) variants are associated with left or biventricular arrhythmogenic cardiomyopathy. Exercise promotes penetrance and sustained ventricular arrhythmias (VA) in classic ARVC. It is unknown if exercise affects risk in DSP variant carriers.

Exercise 40

Exercise Cardiomyopathy Arrhythmia 40

HeartRhythm

MARCH 25, 2025

Ventricular arrhythmias (VAs) may be the first clinical manifestation in pediatric patients with arrhythmogenic cardiomyopathy (ACM). The arrhythmogenicity of exercise testing (ET) remains unclear.

Pediatrics 40

Pediatrics Exercise Cardiomyopathy Arrhythmia 40

Circulation

JANUARY 12, 2025

Circulation, Volume 151, Issue 2 , Page 145-148, January 14, 2025.

Exercise 49

Exercise Cardiomyopathy Circulation 49

Open Heart

JUNE 9, 2022

Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heart failure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.

Quality of Life 52

Quality of Life Cardiac Rehabilitation Exercise Heart Failure 52

Med Page Today

MAY 13, 2024

(MedPage Today) -- The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean change in the peak oxygen uptake.

Exercise 52

Exercise Cardiomyopathy 52

Journal of the American Heart Association

MARCH 7, 2025

BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. for Nterminal proBtype natriuretic peptide) while improving exercise parameters (improved placebocorrected peak oxygen consumption of at least 1.4

Cardiomyopathy 45

Cardiomyopathy Quality of Life Atrial Fibrillation Pharmacology 45

HeartRhythm

APRIL 30, 2024

Hypertrophic cardiomyopathy (HCM) is associated with a predisposition to lethal ventricular arrhythmias. LGE scar burden on MRI is thought to contribute to this risk, but its impact on electrophysiological substrate is not well understood.

Cardiomyopathy 40

Cardiomyopathy Electrophysiology Exercise Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Autonomic remodeling is known to occur in premature ventricular contraction-induced cardiomyopathy (PVC-CM). However, the functional significance of this finding remains unclear.

Cardiomyopathy 40

Cardiomyopathy Exercise 40

Cardiovascular Ultrasound

NOVEMBER 3, 2024

Atrial cardiomyopathy is closely associated with atrial fibrillation (AF), and some patients exhibit no dysfunction at rest but demonstrate evident changes in left atrial (LA) function and LA volume during exe.

Atrial Fibrillation 52

Atrial Fibrillation Exercise Cardiomyopathy Research 52

European Journal of Heart Failure

SEPTEMBER 26, 2023

Exercise training in patients with advanced heart failure and left ventricular assist device (Ex-VAD) trial. 6MWT, 6-min walk test; KCCQ, Kansas City Cardiomyopathy Questionnaire physical domain score; peakVO 2 , peak oxygen consumption; RCT, randomized controlled trial. m (95% CI 16.9, p  = 0.0124), both after 12 weeks. m (95% CI 16.9,

Exercise 40

Exercise Heart Failure Quality of Life Cardiomyopathy 40

Circulation: Genomic and Precision Medicine

NOVEMBER 28, 2023

Background:Limiting high-intensity exercise is recommended for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) due to its association with penetrance, arrhythmias, and structural progression. Guidelines recommend shared decision-making (SDM) for exercise level, but there is little evidence regarding its impact.

Exercise 40

Exercise Cardiomyopathy Arrhythmia Circulation 40

DAIC

MAY 6, 2024

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Circulation

OCTOBER 19, 2023

BACKGROUND:The consequences of exercise-induced premature ventricular contractions (PVCs) in asymptomatic individuals remain unclear. Low PVC counts during exercise and recovery were both associated with MI/HF/LTVA risk, independently of clinical factors: adjusted hazard ratio (HR), 1.2 (1–5 years; 51.1% years; 51.1%

Exercise 40

Exercise Myocardial Infarction Heart Failure Cardiomyopathy 40

EMS 12-Lead

MAY 20, 2022

She reports a known history of Hypertrophic Cardiomyopathy (HCM) with left ventricular outflow tract obstruction and is on daily beta blocker therapy. Furthermore, she denies any hydration since conclusion of exercise. Diagnosis and management of hypertrophic cardiomyopathy: Expert analysis. References Naidu, S. Tower-Rader, A.

Cardiomyopathy 52

Cardiomyopathy Ischemia STEMI Coronary Angiogram 52

European Journal of Heart Failure

DECEMBER 18, 2024

Development of a machine learning model to predict new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy. AF, atrial fibrillation; AUC, area under the receiver-operating characteristic curve; CI, confidence interval; HCM, hypertrophic cardiomyopathy; LVOT, left ventricular outflow tract; MRI, magnetic resonance imaging.

Atrial Fibrillation 40

Atrial Fibrillation Cardiomyopathy Exercise Arrhythmia 40

DAIC

MAY 31, 2024

Given the rapid expansion of sports cardiology, cardiovascular care teams must understand contemporary care and practice management strategies for all athletes—from the elite to the exercise enthusiast.

Cardiac Arrest 111

Cardiac Arrest Exercise Thrombosis Diet 111

The American Journal of Cardiology

SEPTEMBER 21, 2024

Publication date: Available online 20 September 2024 Source: The American Journal of Cardiology Author(s): Agostina M. Fava, Zoran B Popovic, Alaa Alashi, Maran Thamilarasan, Bo Xu, Milind Y.

Exercise 40

Exercise Cardiomyopathy 40

All About Cardiovascular System and Disorders

APRIL 30, 2024

Hypertrophic cardiomyopathy is a genetic disorder with a guarded prognosis which occurs in about 1:500 individuals. The most common symptom of hypertrophic cardiomyopathy is dyspnoea which occurs in 90% of cases and is due to elevated left ventricular diastolic pressures as a consequence of the diastolic dysfunction.

Cardiomyopathy 40

Cardiomyopathy Bicuspid/Mitral Document Arrhythmia 40